ArticleThe Lancet regional health. Europe2025

Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial.

Alexios Matikas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.